Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Fuchs SP, Desrosiers RC.

Mol Ther Methods Clin Dev. 2016 Nov 16;3:16068. doi: 10.1038/mtm.2016.68. eCollection 2016. Review.

2.

Controlling Multicycle Replication of Live-Attenuated HIV-1 Using an Unnatural Genetic Switch.

Yuan Z, Wang N, Kang G, Niu W, Li Q, Guo J.

ACS Synth Biol. 2017 Apr 21;6(4):721-731. doi: 10.1021/acssynbio.6b00373. Epub 2017 Jan 30.

PMID:
28106981
3.

Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV Infection.

Adnan S, Reeves RK, Gillis J, Wong FE, Yu Y, Camp JV, Li Q, Connole M, Li Y, Piatak M Jr, Lifson JD, Li W, Keele BF, Kozlowski PA, Desrosiers RC, Haase AT, Johnson RP.

PLoS Pathog. 2016 Dec 13;12(12):e1006104. doi: 10.1371/journal.ppat.1006104. eCollection 2016 Dec.

4.

High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.

Kannanganat S, Wyatt LS, Gangadhara S, Chamcha V, Chea LS, Kozlowski PA, LaBranche CC, Chennareddi L, Lawson B, Reddy PB, Styles TM, Vanderford TH, Montefiori DC, Moss B, Robinson HL, Amara RR.

J Immunol. 2016 Nov 1;197(9):3586-3596. Epub 2016 Sep 28.

PMID:
27683750
5.

Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines.

Voss JE, Macauley MS, Rogers KA, Villinger F, Duan L, Shang L, Fink EA, Andrabi R, Colantonio AD, Robinson JE, Johnson RP, Burton DR, Haase AT.

AIDS. 2016 Oct 23;30(16):2427-2438.

PMID:
27428745
6.

Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.

Chamcha V, Kannanganat S, Gangadhara S, Nabi R, Kozlowski PA, Montefiori DC, LaBranche CC, Wrammert J, Keele BF, Balachandran H, Sahu S, Lifton M, Santra S, Basu R, Moss B, Robinson HL, Amara RR.

Open Forum Infect Dis. 2016 Feb 11;3(1):ofw034. doi: 10.1093/ofid/ofw034. eCollection 2016 Jan.

7.

Vaccination with Live Attenuated Simian Immunodeficiency Virus (SIV) Protects from Mucosal, but Not Necessarily Intravenous, Challenge with a Minimally Heterologous SIV.

Sutton MS, Burns CM, Weiler AM, Balgeman AJ, Braasch A, Lehrer-Brey G, Friedrich TC, O'Connor SL.

J Virol. 2016 May 27;90(12):5541-8. doi: 10.1128/JVI.00192-16. Print 2016 Jun 15.

8.

Rectal HSV-2 Infection May Increase Rectal SIV Acquisition Even in the Context of SIVΔnef Vaccination.

Guerra-Pérez N, Aravantinou M, Veglia F, Goode D, Truong R, Derby N, Blanchard J, Grasperge B, Gettie A, Robbiani M, Martinelli E.

PLoS One. 2016 Feb 17;11(2):e0149491. doi: 10.1371/journal.pone.0149491. eCollection 2016.

9.

Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques.

Smith SA, Kilgore KM, Kasturi SP, Pulendran B, Hunter E, Amara RR, Derdeyn CA.

J Virol. 2015 Dec 16;90(4):1880-7. doi: 10.1128/JVI.02711-15.

10.

Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING.

Trotard M, Tsopoulidis N, Tibroni N, Willemsen J, Binder M, Ruggieri A, Fackler OT.

J Virol. 2015 Dec 9;90(4):2064-76. doi: 10.1128/JVI.02966-15.

11.

Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.

Lee FH, Mason R, Welles H, Learn GH, Keele BF, Roederer M, Bar KJ.

J Virol. 2015 Dec;89(24):12388-400. doi: 10.1128/JVI.01531-15. Epub 2015 Sep 30.

12.

Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models.

Roederer M.

PLoS Pathog. 2015 Aug 18;11(8):e1005100. doi: 10.1371/journal.ppat.1005100. eCollection 2015 Aug.

13.

Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.

Breed MW, Elser SE, Torben W, Jordan AP, Aye PP, Midkiff C, Schiro F, Sugimoto C, Alvarez-Hernandez X, Blair RV, Somasunderam A, Utay NS, Kuroda MJ, Pahar B, Wiseman RW, O'Connor DH, LaBranche CC, Montefiori DC, Marsh M, Li Y, Piatak M Jr, Lifson JD, Keele BF, Fultz PN, Lackner AA, Hoxie JA.

J Virol. 2015 Oct;89(20):10156-75. doi: 10.1128/JVI.01134-15. Epub 2015 Jul 29.

14.

Analysis of repeated low-dose challenge studies.

Nolen TL, Hudgens MG, Senb PK, Koch GG.

Stat Med. 2015 May 30;34(12):1981-92. doi: 10.1002/sim.6462. Epub 2015 Mar 9.

15.

CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection.

Adnan S, Colantonio AD, Yu Y, Gillis J, Wong FE, Becker EA, Piatak M Jr, Reeves RK, Lifson JD, O'Connor SL, Johnson RP.

PLoS Pathog. 2015 Feb 17;11(2):e1004633. doi: 10.1371/journal.ppat.1004633. eCollection 2015 Feb. Erratum in: PLoS Pathog. 2015 May;11(5):e1004915.

16.

The influence of delivery vectors on HIV vaccine efficacy.

Ondondo BO.

Front Microbiol. 2014 Aug 22;5:439. doi: 10.3389/fmicb.2014.00439. eCollection 2014. Review.

17.

A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.

Kang C, Huang Y, Miller CJ.

Biostatistics. 2015 Apr;16(2):295-310. doi: 10.1093/biostatistics/kxu040. Epub 2014 Sep 3.

18.

Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M Jr, Waterman D, Reeves RK, Masek-Hammerman K, Derdeyn CA, Alpert MD, Evans DT, Kohler H, Müller S, Robinson J, Lifson JD, Burton DR, Johnson RP, Haase AT.

J Immunol. 2014 Sep 15;193(6):3113-25. doi: 10.4049/jimmunol.1400820. Epub 2014 Aug 18.

19.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.

20.

Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication.

Sheppard NC, Jones RB, Burwitz BJ, Nimityongskul FA, Newman LP, Buechler MB, Reed JS, Piaskowski SM, Weisgrau KL, Castrovinci PA, Wilson NA, Ostrowski MA, Park B, Nixon DF, Rakasz EG, Sacha JB.

PLoS One. 2014 Mar 20;9(3):e92012. doi: 10.1371/journal.pone.0092012. eCollection 2014.

Supplemental Content

Support Center